WagnerJ.S., AdsonM.A., Van HeerdenJ.A.: The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment.Ann Surg, 199: 502–508, 1984.
2.
FongY.: Surgical therapy of hepatic colorectal metastasis.CA Cancer J Clin, 49: 231–235, 1999.
3.
AdamR.: Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.Ann Oncol, 14: ii13–ii16, 2003.
4.
BallantyneG.H., QuinJ.: Surgical treatment of liver metastases in patients with colorectal cancer.Cancer, 71: 4252–4266, 1993.
5.
GorogD., TothA., WeltnerJ.: Prognosis of untreated liver metastasis from rectal cancer.Acta Chir Hung, 36: 106–107, 1997.
6.
WoodC.B., GillisC.R., BlumgartL.H.: A retrospective study of the natural history of patients with liver metastases.Clin Oncol, 2: 285–288, 1976.
7.
JaeckD., BachellierP., GuiguetM.: Long-term survival following resection of colorectal hepatic metastases.Br J Surg, 84: 977–980, 1997.
8.
NordlingerB., VaillantJ.C., GuiguetM.: Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases.J Clin Oncol, 12: 1491–1496, 1994.
9.
HughesK.S., SimonR., SonghorabodiS.: Resection of the liver for colorectal carcinoma metastases: a multiinstitutional study of indications for resection.Surgery, 103: 278–288, 1988.
10.
ScheeleJ., StanglR., Altendorf-HofmannA.: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.Br J Surg, 77: 1241–1246, 1990.
11.
ScheeleJ., StanglR., Altendorf-HofmannA.: Resection of colorectal cancer liver metastases.World J Surg, 19: 59–71, 1995.
12.
EkbergH., TranbergK.G., AndersonR.: Determinants of survival in liver resection for colorectal secondaries.Br J Surg, 73: 727–731, 1986.
13.
NordlingerB., GuiguetM., VaillantJ.C.: Surgical resection of colorectal carcinoma metastases in the liver. A prognostic system to improve case selection, based on 1568 patients. Association Française de Chirurgie.Cancer, 77: 1254–1262, 1996.
14.
JatzkoG.R., LisborgP.H., StettnerH.M., KlimpfingerM.H.: Hepatic resection for metastases from colorectal carcinoma: a survival analysis.Eur J Cancer,31A: 41–46, 1995.
15.
ChiappaA., ZbarA.P., BiellaF., StaudacherC.: Survival after repeat hepatic resection for recurrent colorectal metastases.Hepatogastroenterology, 46: 1065–1070, 1999.
16.
TranbergK., BengmarkS.: Metastatic liver tumors of the liver. In: BlumgartL.H. (ed), Surgery of the liver and biliary tract.Churchill Livingstone, Edinburgh, pp 1371–1397, 1994.
17.
SaltzL.B., CoxJ.V., BlankeC.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.N Engl J Med, 343: 905–914, 2000.
18.
DouillardJ.Y., CunninghamD., RothA.D.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.Lancet, 355: 1041–1047, 2000.
19.
KöhneC-H, Van CutsemE., WilsJ.A.: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986.Proc ASCO, 22: 1018 (abstr), 2003.
20.
de GramontA., FigerA., SeymourM.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol, 18: 2938–2947, 2000.
21.
GiacchettiS., ItzhakiM., GruiaG.: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.Ann Oncol, 10: 663–669, 1999.
22.
TournigandC., AndreT., AchilleE.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study.J Clin Oncol, 22: 229–237, 2004.
23.
ScheithauerW., RosenH., KornekG.V., SebestaC., De-pischD.: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.Brit Med J, 306: 752–755, 1993.
24.
ShankarA., LeonardP., RenautA.J.: Neoadjuvant therapy improves resectability rates for colorectal liver metastases.Ann R Coll Surg Engl, 83: 85–88, 2001.
25.
RivoireM., De CianF., MeeusP.: Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma.Cancer, 95: 2283–2292, 2002.
26.
FalconeA., MasiG., AllegriniG.: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil and leucovorin: a pilot study in patients with metastatic colorectal cancer.J Clin Oncol, 20: 4006–4014, 2002.
27.
CornellaP., CasarettiR., De RosaV.: Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.Ann Oncol, 13: 1874–1881, 2002.
28.
QuenetF., NordlingerB., RivoireM.: Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial.Proc ASCO, 22: 3613 (abstr) 2004.
29.
AllenP.J., KemenyN., JarnaginW.: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases.J Gastrointest Surg, 7: 109–115, 2003.
30.
BismuthH., AdamR., LeviF.: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.Ann Surg, 224: 509–520, 1996.
31.
GiacchettiS., PerpointB., ZidaniR.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.J Clin Oncol, 18: 136–147, 2000.
32.
AdamR., AvisarE., AricheA.: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal.Ann Surg Oncol, 8: 347–353, 2001.
33.
DelaunoitT., AlbertsS.R., SargentD.J.: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.Ann Oncol, 16: 425–429, 2005. Epub January 27, 2005.
34.
AlbertsS.R., DonohueJ.H., MahoneyM.R.: Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study.Proc ASCO, 22: 1053 (abstr), 2003.
35.
NomuraM., TakahashiY., MaiM.: Irinotecan as second-line treatment for unresectable metastases of colon cancer.Int J Clin Oncol;3: 117–120, 1998.
36.
DucreuxM., RaoulJ., MartiY.: Enhanced efficacy in patients receiving irinotecan high-dose 260 mg/m2 with 5FU/FA in 1st line metastatic colorectal cancer. Updated results of a phase II study.Proceedings ICACT,203(Feb), 2003.
37.
ZelekL., BugatR., CherquiD.: Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).Ann Oncol, 14: 1537–1542, 2003.
38.
SlaterR., RadstoneL., MatthewesJ.: Hepatic resection for colorectal liver metastases after down-staging with irinotecan improves survival.Proc ASCO, 22: 1287 (abstr), 2003.
39.
PozzoC., BassoM., CassanoA., QuirinoM., SchinzariG., TrigilaN., VelloneM., GiulianteF., NuzzoG., BaroneC.: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.Ann Oncol, 15: 933–939, 2004.
40.
KemenyM.: Hepatic artery infusion of chemotherapy as a treatment for hepatic metastases from colorectal cancer.Cancer J,8(Suppl 1): S82–S88, 2002.
41.
LygidakisN.J., SgourakisG., DedemadiG., SafioleusM.C., NestoridisJ.: Regional chemoimmunotherapy for nonresectable metastatic liver disease of colorectal origin. A prospective randomized study.Hepatogas-troenterology, 48: 1085–1987, 2001.
42.
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-analysis Group in Cancer.J Natl Cancer Inst, 88: 252–258, 1996.
43.
Allen-MershT.G., EarlamS., FordyC., AbramsK., HoughtonJ.: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.Lancet, 344: 1255–1260, 1994.
44.
KemenyN., JarnaginW., GonenM.: Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.J Clin Oncol, 21: 3303–3309, 2003.
45.
BarnettK.T., MalafaM.P.: Complications of hepatic artery infusion: a review of 4580 reported cases.Int J Gastrointest Cancer, 30: 147–160, 2001.
46.
RivoireM., De CianF., MeeusP., NegrierS., SebbanH., KaemmerlenP.: Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma.Cancer, 95: 2283–2292, 2002.
47.
BerberE., PelleyR., SipersteinA.E.: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study.J Clin Oncol, 23: 1358–1364, 2005. Epub January 31, 2005.
48.
LazhortesF., NavarroF., YchouM., DelperoJ.R., RougierP.: Pris en charge thérapeutique des métastases hépatiques des cancers colo-rectaux.Gastroenterologie Clinique et Biologique, 27: B7–B23, 2003.
49.
HallerD.G., AlbertsS., AdamR.: Oncosurge: a therapeutic decision model to optimize the management of colorectal liver metastases. Proceedings Gastrointestinal Cancers Sympsium American Society of Clinical Oncology, abstr 162, 2005.
50.
GuptaA.K., MeltonLJ3rd, PetersenG.M.: Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study.Clin Gastroenterol Hepatol, 3: 150–158, 2005.
